The FDA’s approval process for new psychiatric drugs is broken.  It is time-consuming and costly, and benefits no one—patients, physicians, pharmaceutical companies, managed care organizations, or other payers. To bring a new compound to market, pharmaceutical companies and academic labs invest years (and millions of dollars) in basic research.  When a compound appears promising, it enters … Continue reading FDA approval of psych meds – an alternative